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 2 
Abstract 27 
Activated leukocyte cell adhesion molecule (ALCAM) is expressed on various cell types, including 28 
leukocytes, endothelial cells and certain tumor cells. While ALCAM expression in tumor cells has 29 
been linked with tumor invasion and metastatic spread, the contribution of ALCAM expressed in 30 
cells forming the tumor stroma to cancer progression has not been investigated. In this study, we 31 
made use of ALCAM-deficient (ALCAM-/-) mice to evaluate the role of ALCAM in lung tumor 32 
growth and metastasis. ALCAM-/- mice displayed an altered blood vascular network in the lung 33 
and the diaphragm, indicative of an angiogenesis defect. Absence of ALCAM expression by cells 34 
forming the stromal tumor microenvironment profoundly impacted lung tumor growth in three 35 
different intravenous metastasis models. In the case of Lewis lung carcinoma (LLC), an additional 36 
defect in tumor cell homing to the lungs and a resulting reduction in the number of lung tumor 37 
nodules was observed.  Similarly, when LLC were subcutaneously implanted to study 38 
spontaneous tumor cell metastasis, the rate of LLC metastases to the lungs was profoundly 39 
reduced in ALCAM-/- mice. Taken together, our work demonstrates for the first time the in vivo 40 
contribution of ALCAM to angiogenesis and reveals a novel role of stromally expressed ALCAM 41 
in supporting tumor growth and metastatic spread.  42 43 
 3 
Introduction   44 
Cell adhesion molecules (CAMs) are transmembrane proteins, which are involved in cell-cell and 45 
cell-extracellular matrix (ECM) interactions. Many studies have documented the involvement of 46 
CAMs in various steps of tumor progression and metastatic spread, namely in tumor cell 47 
interaction with the ECM, invasion, expansion of the intra- and peritumoral vasculature, entry and 48 
exit of tumor cells from the circulation and finally metastatic outgrowth in distant organs 1, 2. In 49 
addition, CAMs are crucial for the recruitment and activation of leukocytes during an anti-tumor 50 
immune response 3. Activated leukocyte cell adhesion molecule (ALCAM, CD166) is a member of 51 
the immunoglobulin superfamily and has been implicated in many of the above-mentioned 52 
processes. ALCAM engages in homophilic, as well as heterophilic interactions with its binding 53 
partners CD6, galectin 8 and L1CAM 4-6.  ALCAM expression by T cells 7 and monocytes 8 was 54 
shown to mediate the migration of leukocytes across ALCAM-expressing endothelial cell 55 
monolayers, whereas the interaction of ALCAM expressed on dendritic cells with CD6 expressed 56 
on T cells reportedly contributes to T cell activation in vitro 9, 10. In addition, ALCAM expressed by 57 
vascular endothelial cells was shown to support angiogenic processes in vitro 11, 12. Although the 58 
expression of ALCAM in blood vessels in vivo has been demonstrated in the human and murine 59 
central nervous system (CNS) 7, 13, the human skin 11, the rat lung 14 and the murine liver and lung 60 
11, 15, its in vivo contribution to angiogenesis has not been investigated to date. In this context, our 61 
group has recently described the expression of ALCAM in lymphatic endothelial cells and its 62 
involvement in the formation of lymphatic vessels, thereby providing the first in vivo evidence of 63 
the relevance of ALCAM for endothelial cell biology 11. Moreover, a recent study has reported the 64 
role of ALCAM in regulating the expression of tight junction proteins and controlling vascular 65 
permeability of the blood brain barrier 13. 66 
In addition to leukocytes and endothelial cells, several other cells such as neurons 16, certain 67 
epithelial cells 17 and keratinocytes 18 reportedly express ALCAM. Moreover, ALCAM expression 68 
by cancer cells has been linked with the grade of tumor malignancy, apoptotic resistance, 69 
epithelial-mesenchymal transition and patient prognosis 3. For example, in gastric cancer 19, 70 
colorectal cancer 20, 21, pancreatic cancer22, prostate cancer 23, 24, or melanoma 25-27 ALCAM 71 
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expression was shown to positively correlate with cancer progression. The tumor stroma, which 72 
consists of cells forming the tumor vasculature, immune cells, fibroblast and the ECM, is known 73 
to directly impact tumor cell survival, tumor growth and progression 28-30. However, up to now the 74 
contribution of stromal ALCAM to in vivo tumor growth has not been examined. In this study, we 75 
investigated lung tumor growth and metastatic spread in ALCAM-/- compared to wild-type (WT) 76 
mice. Performing experiments in three different intravenous lung metastasis models we show that 77 
absence of ALCAM expression in stromal cells markedly reduced metastatic outgrowth in the 78 
lungs of ALCAM-/- compared to WT mice. The tumor growth retardation was associated with an 79 
angiogenesis defect and – in the case of LLC – with reduced ability of tumor cells to home to the 80 
lungs of ALCAM-/- mice. In sum, our work reveals a novel contribution of ALCAM expressed by 81 
cells forming the stromal tumor microenvironment to metastatic spread and tumor outgrowth in 82 
the lung. 83 
 84 
 85 
 86 
Materials and Methods 87  88 
Mice 89 
WT C57BL/6-J mice (Janvier, Genest-Saint-Isle, France) and ALCAM-/- mice 16 obtained from 90 
Jackson Laboratories (Bar Harbor, ME, USA) were housed in the animal facility of ETH Zurich or 91 
of the University of Zurich. All experiments were approved by the Cantonal Veterinary Office 92 
Zurich. 93 
 94 
Cell lines  95 
The melanoma cell line B16F10 cell line  (B16F10; Caliper, Hopkinton, MA, USA) transfected with 96 
luciferase (B16F10-luc2) was kindly provided by Dr. Michael Detmar, ETH Zurich. Cells were 97 
cultured in DMEM (Invitrogen, Carlsbad, CA, USA) supplemented with 10 % FCS (Life 98 
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Technologies, Carlsbad, CA, USA) and 1 % antibiotic-antimycotic (Life Technologies).  The colon 99 
adenocarcinoma cell line MC38 GFP 31, the LLC cell line 32 (from ATCC) as well as LLCs 100 
lentivirally transfected with luciferase were cultured as previously described 33. Human umbilical 101 
vein endothelial cells (HUVECs; Promocell, Heidelberg, Germany) were cultured on plates coated 102 
with 10 µg/ml collagen type I (Advanced BioMatrix, Poway, CA, USA) and 10 µg/ml fibronectin 103 
(Merck Millipore, Darmstadt, Germany) in EGM-2MV medium without VEGF-A (Lonza, Basel, 104 
Switzerland). Mouse Mile Sven-1 (MS-1) cells 34 were cultured in DMEM (Sigma-Aldrich, St. 105 
Louis, MO, USA) supplemented with 5 % FCS (Life Technologies) and 1 % antibiotic-antimycotic 106 
(Life Technologies).  107 
 108 
Scratch-wound assay 109 
Confluent HUVEC and MS-1 monolayers grown in 24-well plates were cultured for 24 hours in 110 
starvation medium containing FCS (Life Technologies; HUVEC: 2%; MS-1: 5%) and 1 % 111 
antibiotic-antimycotic solution (Life Technologies). Assays were performed as described in 11, 112 
using anti-human ALCAM (R&D Systems, Abingdon, UK) or goat IgG (all at 10 μg/ml) in 113 
starvation medium. For HUVECs assays were performed in presence of human VEGF-A 114 
(20 ng/ml; PeproTech, London, UK) in starvation medium.  115 
 116 
Immunohistology of murine tissues 117 
Immunohistology of murine diaphragms was performed as previously described 11. In brief, 118 
diaphragm whole mounts were blocked in 1 % BSA, 0.05 % sodium azide, 0.01 % Triton-x and 119 
5% normal donkey serum (Sigma-Aldrich) in PBS for 1 h and stained with rat anti-mouse CD31 120 
(BD Bioscience, Franklin Lakes, NJ, USA) in PBS overnight. The next day, diaphragms were 121 
washed and incubated for 2 hours with anti-rat AlexaFlour 488-conjugated secondary antibody 122 
(Invitrogen). Images were acquired on a LSM 710 FCS confocal microscope (Carl Zeiss Inc., 123 
Jena, Germany) using 10x objective (NA of 0.3) and analyzed with ImageJ software. To 124 
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exclusively analyze blood vessels, CD31+ lymphatic vessels (identified by their CD31dim staining 125 
and large vessel diameter) were removed from the image prior to analysis.  126 
For immunohistological analysis of mouse lungs, mice were euthanized and perfused with PBS 127 
followed by a 4 % PFA solution for fixation. After 2 days in 4 % PFA, lungs were embedded in 128 
paraffin. In the case of α-smooth muscle actin (αSMA) staining, lung sections (6 µm) were stained 129 
on a staining robot (BondMax, Leica Microsystems, Wetzlar, Germany) with anti-mouse αSMA 130 
antibody (Sigma-Aldrich), followed by incubation with secondary rabbit anti-mouse-IgG (Abcam, 131 
Cambridge, UK). Final detection of bound antibody was performed using the Bond Polymer 132 
Refine detection DAB-Kit (Leica Microsystems).  For the vWF staining, lung sections were 133 
incubated at 60 °C for 10 min, followed by deparaffinization and rehydration. Sections were 134 
incubated for 1 hour at room temperature in blocking solution (3 % BSA, 0.1 % NP40 (both from 135 
Sigma-Aldrich) in PBS).  Subsequently, rabbit anti-mouse vWF (Dako, Glostrup, Denmark) in 136 
blocking solution was added overnight at 4 °C. The next day, sections were washed and anti-137 
rabbit AlexaFluor 594 (Invitrogen) was applied for 1 hour at room temperature in PBS. Sections 138 
were mounted using Mowiol (Calbiochem, San Diego, CA, USA).  For the quantification of the 139 
vWF+ or αSMA+ vessel area, five (vWF) or nine (αSMA) images per lung were acquired. Vessels 140 
that were completely visible within the field of view were encircled using Adobe Photoshop CS5 141 
(Adobe System, San Jose, CA), followed by quantification of the vessel area and vessel number.  142 
For the analysis of MC38 tumor vascularization and vessel maturation, OCT-embedded, frozen 143 
sections (6 µm) were fixed in acetone (2 min at -20 °C) and methanol (5 min at 4 °C) followed by 144 
two washing steps in Tris-buffered saline (TBS). Sections ware stained with rat anti-mouse CD31 145 
(clone MEC13.3, BD Pharmingen, San Jose, CA, USA) and rabbit anti-mouse NG2 (polyclonal 146 
antibody, Merck) in antibody diluent (Zytomed Systems, Berlin, Germany) overnight at 4 °C. After 147 
washing with TBS, AlexaFluor 488- and 594-coupled secondary antibodies (Invitrogen) were 148 
added for detection. Sections were mounted using Mowiol (Calbiochem). For quantification of 149 
CD31+ and CD31+ NG2+ vessels, images of three vascularized areas per tumor nodule were 150 
acquired (as described below) and analyzed using ImageJ. The area of CD31+ vessels was 151 
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determined after tresholding. Subsequently the percentage of vessels that were NG2+ among 152 
CD31+ vessels was determined.  153 
For the analysis of macrophage infiltration into MC38 tumor nodules, OCT-embedded, frozen 154 
sections (6 µm) were fixed in acetone (2 min at -20 °C) and methanol (5 min at 4 °C) followed by 155 
two washing steps in PBS. Sections were incubated for 45 minutes at room temperature in 156 
blocking solution (2 % BSA, 5 % normal donkey serum (NDS), 0.1% TritonX (all from Sigma-157 
Aldrich) in PBS).  Subsequently, rat anti-mouse F4/80 (clone BM8, eBioscience, San Diego, CA, 158 
USA) and goat anti-mouse CD206 (polyclonal antibody, R&D) in PBS with 5% NDS were added 159 
overnight at 4 °C. After washing with PBS, AlexaFluor 488- and 594-coupled secondary 160 
antibodies (Invitrogen) were added for detection. Sections were mounted using Mowiol 161 
(Calbiochem). For quantification of F4/80+ and F4/80+ CD206+ cells, three images per tumor 162 
nodule were acquired (as described below) and analyzed using ImageJ.  163 
For the quantification of tumor nodule area, frozen MC38 sections were stained with 164 
haemotoxylin/eosin (H&E) and stitched images of the entire tumor nodule were acquired and 165 
analyzed using Adobe Photoshop CS5 (Adobe System). Images were acquired with an Axioskop 166 
2 MOT plus microscope (Carl Zeiss Inc.) using the following objectives: 10 x objective, NA of 0.3 167 
(for lung sections stained for vWF and αSMA); 20 x objective, NA of 0.5 (for MC38 lung tumor 168 
sections stained for CD31/NG2 and F4/80/CD206); and 5 x objective; NA of 0.15 (H&E stainings). 169 
The microscope was equipped with an AxioCam MRm monochrome digital camera (Carl Zeiss 170 
Inc.) and AxioVision 4.4 software (Carl Zeiss Inc.).  171 
 172 
Immunohistology of human tissues 173 
6 µm sections of human foreskin and human lungs (Zyagen, USA) were analyzed for ALCAM 174 
expression. After fixation with acetone (2 minutes at -20 °C) and 80% methanol (5 minutes at 175 
4°C), sections were stained with mouse anti-human CD31 (Dako, clone JC70A) or mouse anti-176 
human αSMA–Cy3 (Sigma, clone 1A4) and goat anti-mouse ALCAM (R&D, polyclonal antibody) 177 
or corresponding goat isotype control (Invitrogen) overnight at 4°C in a PBS blocking solution 178 
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containing 2% BSA, 5% normal donkey serum and 0.1% tween (all from Sigma-Aldrich). After 179 
washing, anti-mouse Alexa Fluor 594 and anti-goat Alexa Fluor 647 (Invitrogen) were added for 1 180 
hour at room temperature.  Confocal images were acquired at a LEICA TCS SP8 microscope 181 
using a 20x objective (NA of 0.7, Leica). 182 
 183 
FACS analysis  184 
FACS analysis of in vitro-cultured cells and tissues was performed as previously described 11. In 185 
brief, in vitro-cultured cells were washed with PBS and detached using accutase (Sigma-Aldrich). 186 
For tissue FACS, tissues were digested in PBS supplemented with 4 mg/ml collagenase IV 187 
(Gibco) for 1h at 37°C. In the case of lungs, collagenase IV was resuspended in Grey’s Balanced 188 
Salt Solution (GBSS, Sigma-Aldrich). Cell suspensions were stained with anti-mouse CD31-APC, 189 
anti-mouse CD45-PerCP, CD45-APC and podoplanin-PE and corresponding isotype controls (all 190 
from Biolegend, San Diego, California, USA). Dead cells were excluded using Zombie dye 191 
(Biolegend). ALCAM expression was detected by staining with goat anti-mouse ALCAM antibody 192 
and corresponding AlexaFluor488- or PE-labeled secondary antibodies (Invitrogen). Data were 193 
acquired on a BD FACSCanto (BD Bioscience, Franklin Lake, NJ, USA) using FACSDiva 194 
software (BD Bioscience) and analyzed with FlowJo software 8.7.1. (Treestar, Ashland, TN, 195 
USA).  196 
 197 
Homing studies 198 
12-15 week old WT or ALCAM-/- mice were used for homing studies. Prior to tumor cell injection, 199 
tumor cells (LLC or B16F10) were stained with 5 mM CFSE (Invitrogen) for 15 min at 37°C in 200 
PBS, followed by neutralization of unused dye with equal volumes of media. After washing cells 201 
twice with PBS, mice were injected with 1x106 cells i.v.. 24 hours later, mice were sacrificed, 202 
perfused with PBS and the lungs were harvested. Lungs were cut in small pieces and digested 203 
for 45 min at 37°C in 4 mg/ml collagenase IV (Gibco) in PBS. Subsequently, the lungs were 204 
passed through a 40 µm cell strainer and subjected to red blood cell lysis using ACK buffer. Lung 205 
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single cell suspensions were stained with CD45-APC (Biolegend). CD45- CFSE+ tumor cells were 206 
quantified by FACS with the help of counting beads (Invitrogen).  207 
 208 
Tumor models 209 
12-15 week old WT or ALCAM-/- mice were used for tumor studies. For the lung metastasis model 210 
mice were injected i.v. with tumor cells (B16F10-Luc: 1x106; LLC: 1.5x105; MC38-GFP 3x105). 211 
After 12-26 days (B16F10 and LLC: 12-14 days; MC38: 26 days) mice were sacrificed and the 212 
tumor burden was analyzed. B16F10 tumor growth was monitored in vivo by intraperitoneal (i.p.) 213 
injection of 150 mg luciferin/kg body weight and imaging the luminescent signal in the thorax 20 214 
min later with an IVIS Spectrum imaging system (Caliper) under isoflurane anesthesia. At the end 215 
of the experiment, mice were sacrificed and the luciferase signal was measured in excised lungs 216 
and in lung single cell suspensions (see below). For the spontaneous lung metastasis model, 217 
mice were injected s.c. with 0.2x106 LLC cells. Primary tumors were resected after 21 or 24 days. 218 
The metastatic burden was quantified three weeks later using an IVIS Spectrum imaging system 219 
(Caliper), as mentioned above.   220 
 221 
In vitro luciferase activity assay  222 
Lung tissue was homogenized in lysis buffer containing 25 mM Tris‐Cl pH 7.8 (Fluka), 2 mM 223 
EDTA (Sigma-Aldrich), 1 mM dithiothreitol (DTT, Promega, Madison, WI, USA), 10 % glycerol 224 
(ABCR, Karlsruhe, Germany), 1 % Triton X-100 (Fluka) and one Complete Mini, EDTA‐free 225 
Protease Inhibitor Tablet (Roche, Basel, Switzerland)  (1 tablet was added to 10 ml of lysis 226 
buffer). Samples were homogenized using a TissueLyser (Qiagen, Venlo Netherlands; Retsch, 227 
Haan, Germany) followed by centrifugation. Luciferase activity was measured with an IVIS 228 
Spectrum (Caliper) using 25 µl tissue lysate and 50 µl assay buffer, which consisted of 20 mM 229 
Tris‐Cl (Fluka), 1.1 mM MgCl (Fluka), 2.7 mM MgSO4 x 7H2O (Fluka), 0.1 mM EDTA, 33.3 mM 230 
DTT (Promega, Madison, WI, USA), 530 µM ATP (Sigma-Aldrich) and 400 µM luciferin (Caliper).  231 
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Statistical data analysis 232 
Statistical analysis was performed using Prism 6 (GraphPad Software, La Jolla, CA, USA). 233 
Normally distributed data was analyzed using the student's t-test or one-way ANOVA (more than 234 
two groups) and are presented as mean ± standard error (SEM). To test for significant 235 
differences in the rate of metastases a chi-squared test was applied. Significant outliers were 236 
identified based on Grubbs test and excluded. Differences were considered statistically significant 237 
when p < 0.05.   238 
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Results 239 
 240 
ALCAM is expressed in the human and murine vasculature and contributes to in vitro 241 
angiogenesis  242 
We have recently described an in vivo role for ALCAM in the formation of the lymphatic network 243 
in mice 11. Moreover, several studies have previously reported on the expression of ALCAM in 244 
blood vessels 7, 11, 14, 15 and on its involvement in endothelial cell biology in vitro 11, 12.  In 245 
agreement with previous findings 11, we detected ALCAM expression in the vasculature of human 246 
skin (Fig. 1A). Moreover, we identified ALCAM-positive blood vessels in tissue sections of human 247 
lung (Fig. 1B). High magnification confocal images of the vasculature in the human lung revealed 248 
that ALCAM was primarily expressed in endothelial cells but not in vessel-surrounding mural cells 249 
(Fig. S1A,B). Interestingly, in the mouse, FACS analysis performed on tissue single cell 250 
suspensions revealed ALCAM expression in endothelial cells derived from the murine lung (Fig. 251 
1C), but not from murine skin (Fig. 1D). Moreover, ALCAM was also expressed by non-252 
endothelial stromal cells (i.e. fractions of CD31-CD45-podoplanin+ and CD31-CD45-podoplanin- 253 
cells; Fig. S1C,D). We next performed in vitro endothelial cell migration assays with ALCAM-254 
expressing human umbilical vein endothelial cells (HUVECs) and the immortalized murine blood 255 
vascular endothelial cell line MS-1 34 (Fig. 1E,F). In both cell types, the ability of the endothelial 256 
cells to migrate into a cell-free area was significantly reduced in presence of an ALCAM blocking 257 
antibody (Fig. 1G,H), confirming that ALCAM supports angiogenic processes in vitro.   258 
 259 
ALCAM contributes to angiogenesis in vivo  260 
To investigate whether ALCAM contributes to angiogenesis in vivo, we analyzed the blood 261 
vasculature in the lung and the diaphragm of ALCAM-/- mice 16. Performing whole mount analyses 262 
in the diaphragm of pups we found that the total area covered by CD31+ blood vessels as well as 263 
the average blood vessel diameter were markedly reduced in ALCAM-/- compared to WT 264 
diaphragms (Fig. 2A-C). Moreover, when staining murine lung sections for the blood vascular 265 
marker von Willebrand Factor (vWF; Fig. 2D) we observed that the size of vWF+ vessels was 266 
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profoundly reduced in ALCAM-/- compared to WT mice (Fig. 2E). By contrast, when staining 267 
murine lung sections with the pericyte marker alpha smooth muscle actin (αSMA; Fig. 2F), no 268 
difference in the size of αSMA+ vessels, which typically represent the larger vessels, was 269 
observed (Fig. 2G). However, the total number of αSMA+ vessels (Fig. 2H) was significantly 270 
reduced. Taken together, these results revealed an angiogenesis defect in the lung and the 271 
diaphragm and suggested general alterations in the blood vasculature of ALCAM-/- mice. 272 
 273 
Growth of B16F10 lung metastases is reduced in ALCAM-/- mice 274 
Given the expression of ALCAM on human and murine blood vessels in the lung (Fig. 1B,C) and 275 
its impact on in vivo angiogenesis  (Fig. 2 D-H), we next investigated tumor growth in this organ. 276 
To this end, mice were injected intravenously (i.v.) with a luciferase-expressing B16F10 277 
melanoma cell line. When subsequently monitoring luciferase activity over 12 days by IVIS we 278 
found that luciferase signals were consistently lower in ALCAM-/- compared to WT mice (Fig. 279 
3A/B). The reduced metastatic burden in ALCAM-/- compared to WT mice was confirmed at the 280 
end of the study, by measuring the luciferase activity in excised lungs (Fig. 3C) or in lung 281 
homogenates (Fig. 3D). No significant differences were found when quantifying visible lung 282 
metastases in WT and ALCAM-/- mice (Fig. 3E), or when performing tumor cell homing studies 283 
(Fig. S2), suggesting that the loss of stromal ALCAM expression did not affect the ability of 284 
ALCAM-expressing B16F10 cells (Fig. 3F) to home and seed to the lung. By contrast, the overall 285 
area covered by visible metastases was profoundly reduced in ALCAM-/- mice (Fig. 3G). 286 
Moreover, when analyzing the size distribution of metastases in both genotypes, we observed 287 
that ALCAM-/- mice had almost no large metastases (defined as metastases with a diameter of > 288 
350 µm), but an increased number of small metastases (diameter < 200 µm) (Fig. 3H). Taken 289 
together, these findings suggested a growth disadvantage of B16F10 metastases in the lungs of 290 
ALCAM-/- mice.  291 
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Stromal ALCAM deficiency reduces MC38 tumor growth and angiogenesis  292 
We next performed similar experiments with MC38 adenocarcinoma cells (Fig. 4A), which form 293 
fewer but larger tumor nodules in the lungs upon i.v. injection (Fig. 4B). When dissecting the 294 
lungs 24-28 days after tumor cell injection, no difference in tumor nodule numbers was observed 295 
between the genotypes (Fig. 4C). However, the average lung tumor nodule weight was 296 
profoundly reduced in ALCAM-/- mice (Fig. 4D), confirming the metastatic growth defect 297 
previously observed in the B16F10 model. In line with the reduced tumor weight, H&E staining 298 
revealed that also the average tumor area (Fig. 4E) and the overall percentage of large tumors 299 
(Fig. 4F,G) was reduced in ALCAM-/- compared to WT mice. To investigate whether the reduction 300 
in tumor size was caused by a defect in angiogenesis, we analyzed tumor vascularization by 301 
immunofluorescence. No Lyve-1+ lymphatic vessels could be detected within the tumor nodules 302 
(data not shown). Therefore, all vessels stained by the pan-endothelial marker CD31 were 303 
assumed to be blood vessels. In support of our hypothesis, the tumor area covered by CD31+ 304 
vessels was significantly reduced in ALCAM-/- mice, indicating a defect in tumor angiogenesis 305 
(Fig. 4H). Tumor blood vessels are known to grow in an uncontrolled manner and typically display 306 
a less mature phenotype, as manifested by reduced pericyte coverage 35. When co-staining 307 
tumor nodule sections for the pericyte marker melanoma-associated antigen NG2 (NG2) 35, 36 and 308 
CD31, we observed that the vasculature of ALCAM-/- mice displayed an increased number of 309 
mature, i.e. NG2+ vessels (Fig. 4I). Overall, these findings suggested that, in comparison to the 310 
tumor vasculature of WT mice, ALCAM-/- mice displayed less aberrant tumor neoangiogenesis. 311 
Notably, numbers of tumor-infiltrating F4/80+ and of F4/80+CD206+ M2-like macrophages 37, 312 
which are considered pro-angiogenic 38, were similar in both genotypes (Fig. S3), indicating that 313 
these cells did not contribute to the differences in tumor neovascularization observed between 314 
WT and ALCAM-/- mice.    315 
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Stromal ALCAM deficiency reduces LLC homing and tumor growth in the lungs  316 
To confirm the observed tumor growth defect in a further model, we performed similar 317 
intravenous metastasis studies using LLC cells, which express high levels of ALCAM (Fig. 5A). 318 
Also upon LLC injection, a growth defect at the level of single tumor nodules was observed in the 319 
lungs of ALCAM-/- compared to WT mice (Fig. 5B/C). Moreover, in comparison to WT mice, total 320 
numbers of LLC tumor nodules were significantly reduced in the lungs of ALCAM-/- mice (Fig. 321 
5D). To investigate potential differences in tumor cell seeding to the lung, we injected 322 
fluorescently labeled LLC i.v. and quantified tumor cell numbers in the lungs after 24 hours by 323 
FACS. This analysis revealed that LLC homing was significantly reduced into the lungs of 324 
ALCAM-/- compared to WT mice (Fig. 5E,F).   325 
 326 
Stromal ALCAM deficiency leads to reduced spontaneous metastases to the lung and to 327 
tumor-draining LNs 328 
In a next step we set out to investigate the metastatic process in a more physiological context. To 329 
this end, luciferase-expressing LLC cells were subcutaneously (s.c.) implanted in the flank of WT 330 
and ALCAM-/- mice and tumors were allowed to grow for 21-24 days. Subsequently, tumors were 331 
resected, and spontaneous metastasis to different organs was analyzed three weeks later. 332 
Surprisingly, s.c. implanted primary LLC tumors displayed a moderate growth advantage in 333 
ALCAM-/- compared to WT control mice (Fig. 6A,B). No difference in blood vessel density was 334 
observed in primary tumors of ALCAM-/- and WT mice (Fig. 6C). In fact, we could not detect 335 
ALCAM in the LLC tumor vasculature (Fig. 6D), in line with our previous observation that ALCAM 336 
is not expressed in the murine dermal vasculature under physiological conditions (Fig. 1D). To 337 
allow for a better comparison of the spontaneous metastasis process, groups of mice with 338 
similarly sized tumors were created. Specifically, only WT and ALCAM-/- mice with primary tumors 339 
ranging from 200-1000 mg at the time point of resection were selected and kept in the study (Fig. 340 
6E). Three weeks after primary tumor resection, all animals were sacrificed and luciferase activity 341 
in the lung, liver and inguinal lymph nodes (LNs) was measured. This analysis revealed a 342 
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significant reduction in the overall metastatic burden in ALCAM-/- mice compared to WT controls 343 
(Fig. 6F-J and Fig. S4). In agreement with the reduced number of tumor nodules and tumor cell 344 
homing observed upon i.v. injection of LLC (Fig. 5D-F), a dramatic reduction in tumor metastasis 345 
to the lungs was observed in ALCAM-/- mice (Fig. 6H). Interestingly, metastasis to tumor-draining 346 
LNs was also significantly reduced (Fig. 6I), whereas no difference in the rate of metastasis to the 347 
liver was observed (Fig. 6J). Taken together, our work reveals a novel contribution of stromally 348 
expressed ALCAM in supporting metastatic spread and tumor outgrowth in the lungs and tumor-349 
draining LNs.   350 
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Discussion 351 
In this study we have investigated whether and how expression of ALCAM by cells that form the 352 
stromal tumor microenvironment contributes to tumor growth and metastatic spread. In the past, 353 
various studies have already documented the relevance of tumor cell-expressed ALCAM to tumor 354 
cell migration and invasion 25, 39-41, and metastasis 3, 23, 25. On the other hand, several studies have 355 
reported on the expression and function of ALCAM in leukocytes 6-8, 10 and in endothelial cells 8, 11, 356 
12, 26. Since these cells are important constituents of the tumor stroma, the latter findings indirectly 357 
already suggested a more complex role of ALCAM in tumor growth and progression. Using 358 
ALCAM-deficient mice we now show for the first time that not only tumor cell-expressed but also 359 
stromally-expressed ALCAM may alter tumor growth and metastatic spread by affecting tumor 360 
angiogenesis and tumor cell homing.  361 
Performing experiments in three different intravenous pulmonary metastasis models (i.e. B16F10, 362 
LLC and MC38) we observed that tumor growth in the lung was consistently reduced in ALCAM-/- 363 
compared to WT mice. Expansion of tumors is highly dependent on the formation of blood 364 
vessels 42.  Analyzing the blood vasculature in the Iungs and in the diaphragm of ALCAM-/- mice 365 
we could show that loss of ALCAM indeed compromised the formation of the blood vascular 366 
network in vivo. This finding was further substantiated by our immunohistological analysis of lung 367 
tumor nodules in the MC38 metastasis model, which confirmed that the reduced tumor growth 368 
observed in ALCAM-/- mice was associated with a defect in tumor angiogenesis: Absence of 369 
ALCAM expression on stromal cells led to a reduction in tumor blood vessel density and 370 
increased the proportion of mature and likely quiescent vessels. Whether this angiogenesis 371 
defect is entirely dependent on the lack of ALCAM expression in the blood vasculature or 372 
potentially also supported by the lack of ALCAM on other stromal cells will need to be explored 373 
further.  374 
Our findings revealed that the blood vasculature was compromised in the lung of ALCAM-/- mice. 375 
This might suggest that the reduced metastatic burden observed in our i.v. metastasis models 376 
could simply be explained by anatomic differences in the lungs of ALCAM-/- compared to WT 377 
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mice. However, we did not observe that tumor nodule numbers were consistently decreased in 378 
ALCAM-/- mice in the three different i.v. metastasis models investigated. In fact, a significant 379 
reduction in tumor nodule numbers and in tumor cell homing was only observed with LLC, both 380 
upon i.v. injection of tumor cells (Fig. 5E,F) as well as in the more physiological model of 381 
spontaneous metastasis from s.c. grafted primary tumors (Fig. 6H). This argues against a mere 382 
anatomic explanation for the reduced metastatic burden observed in the lungs of ALCAM-/- mice. 383 
The exact molecular interaction partners that could account for the homing defect observed in the 384 
case of LLC are not clear at this point. ALCAM is known to engage into homophilic as well as 385 
heterophilic interactions 4-6. Given that LLC and B16F10 cells expressed similar levels of ALCAM 386 
(Fig. 5A & 3F), but a homing defect was only observed in the LLC model (Fig. 5E,F and Fig. S2), 387 
it is likely that tumor cell homing to the lungs does not depend on homophilic ALCAM-ALCAM 388 
interactions. Therefore, differential expression of other ALCAM binding partners 4-6 might explain 389 
the differences in the ALCAM dependence of tumor cell homing to the lung that was observed in 390 
the B16F10 and LLC models. Of interest in this regard is another study which has recently 391 
identified a role for the ALCAM binding partner L1CAM in the adhesion of breast cancer cells to 392 
ALCAM-expressing blood vascular endothelium in vitro 43. However, we presently do not know 393 
whether differences in L1CAM expression might explain the homing phenotypes observed in our 394 
models. Moreover, besides L1CAM or other ALCAM binding partners, also other adhesion 395 
molecules expressed on the tumor cells could compensate for loss of endothelial ALCAM 396 
expression during tumor cell homing. Finally, it is also possible that alterations in tumor cell 397 
homing might be caused indirectly by leukocytes that contribute to the tumor cell extravasation 398 
process 33, 44-48.  399 
Surprisingly we found that the growth of s.c. grafted primary tumors was slightly increased in 400 
ALCAM-/- compared to WT mice. In contrast to the angiogenesis defect observed in the lungs, 401 
which likely resulted in reduced growth of pulmonary tumor nodules, angiogenesis was not 402 
compromised in s.c. grafted tumors (Fig. 6C). This is in line with our observation that in mice 403 
ALCAM is not expressed in the vasculature of the dermis or of s.c. grafted tumors. The fact that 404 
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loss of ALCAM had an overall growth-promoting effect on s.c. grafted tumors suggests that  405 
ALCAM expression in the tumor stroma not only supports angiogenesis (if expressed in the 406 
vasculature), but also exerts tumor-suppressive functions. Although not further investigated in this 407 
study, it is likely that loss of ALCAM might compromise the anti-tumor immune response. For 408 
example, ALCAM was shown to support T cell activation, by stabilizing the immunologic synapse 409 
9, 10, 49. Moreover, ALCAM has been implicated in leukocyte extravasation across blood vascular 410 
endothelium 7, 8. Interestingly, besides reducing spontaneous metastasis from primary LLC 411 
tumors to the lungs (Fig. 6H), loss of ALCAM also appeared to reduce the rate of LLC metastasis 412 
to draining LNs (Fig. 6I), but not to the liver (Fig. 6J). We have previously detected ALCAM 413 
expression in the vasculature of the skin-draining LNs and in the liver (11 and data not shown).  414 
The reason why ALCAM deficiency did not affect LLC metastasis to the liver is unclear, but could 415 
be linked with the expression of other adhesion molecules in the hepatic vasculature, which  416 
might compensate for loss of ALCAM, or with the special blood flow conditions in the liver. In the 417 
case of LN metastasis, it remains unclear at this point whether metastasis occurred via the blood 418 
vasculature, or rather via tumor-draining lymphatic vessels. Given that the murine dermal 419 
vasculature does not express ALCAM, a defect in lymphatic migration of tumor cells could only 420 
have occurred at the level of the ALCAM-positive lymphatics in the LN. It is worth noticing that in 421 
the lung and also in the diaphragm we found ALCAM to be higher expressed in lymphatic vessels 422 
compared to blood vessels (Fig. 1C and data not shown). Thus, it is perceivable that in other 423 
murine tissues, or in human skin in which ALCAM is expressed in the lymphatic vasculature (11 424 
and Fig. 1A), ALCAM expression by (peri)tumoral lymphatics might directly impact tumor cell 425 
metastasis to draining LNs.  426 
Overall, our data reveal a novel contribution of stromal ALCAM expression to tumor growth and 427 
metastatic spread and suggest an important role of ALCAM expressed in blood vessels in 428 
supporting tumor angiogenesis. Moreover, our findings reveal that ALCAM expression in the lung 429 
may additionally support tumor cell homing and seeding to this organ. These findings suggest 430 
that ALCAM blockade could be beneficial for inhibiting tumor cell metastasis and tumor 431 
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(lymph)angiogenesis. The fact that we detected ALCAM expression in the vasculature of human 432 
lung and skin (Fig. 1A,B) strengthens the potential translational relevance of our findings.   433 
 434 
 435 
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Figure Legends 587 
 588 
Figure 1: ALCAM is expressed in the human and murine vasculature and contributes to in 589 
vitro angiogenesis. (A,B) Immunofluorescence analysis of human skin (A) and lung (B) tissue 590 
sections, demonstrating expression of ALCAM in CD31+ vessels. Row labeling: ALCAM staining; 591 
performed with primary goat anti-ALCAM. Isotype staining: performed with primary goat isotype 592 
control antibody. Scale bars:  100 μm. Representative images from n=3 (skin) and n=2 (lung) 593 
different biopsy samples are shown (C,D) Single cell suspensions were generated from murine 594 
lungs (C) and ear skin (D) and stained for CD31, podoplanin and CD45. Blood vascular 595 
endothelial cells (BECs) and lymphatic endothelial cells (LECs) were identified by gating on 596 
CD45-CD31+podoplanin- (BECs) or CD45-CD31+podoplanin+ (LECs) cells, respectively. Black 597 
open histogram: αALCAM staining; grey tinted histogram: isotype control. Representative data 598 
from one out of three similar experiments are shown. (E,F) FACS analysis of ALCAM expression 599 
in (E) HUVECs and (F) MS-1 cells. Black open histogram: αALCAM staining; grey tinted 600 
histogram: isotype control. (G,H)  Scratch-wound assay: A cell-free zone was introduced into 601 
confluent HUVEC or MS-1 monolayers and the effect of ALCAM blockade on scratch closure, 602 
which represents migration of bordering LECs into the cell-free zone, was analyzed 12 hours 603 
later. (G) Representative images taken from an experiment with performed HUVECS (H) Results 604 
from HUVEC and MS-1 scratch assays. Data from one out of three (HUVEC) or five (MS-1) 605 
experiments are shown. **P < 0.01, ***P < 0.001 606 
  607 
Figure 2: ALCAM-/- mice display an abnormal vascular phenotype in the diaphragm and the 608 
lung in vivo. (A-B) PFA-fixed diaphragms of six-day-old WT or ALCAM-/- pups were 609 
immunofluorescently stained for the panendothelial marker CD31. To analyze blood vessels only, 610 
CD31+ lymphatic vessels (identified by their CD31dim staining and large vessel diameter) were 611 
removed from the image using ImageJ software. (A) Representative images taken from WT and 612 
ALCAM-/- diaphragms. Scale bar = 200 μm.  Quantification of (B) the total area covered by CD31+ 613 
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blood vessels and (C) the diameter of CD31+ blood vessels. N=7-9 mice per group. (D-L):  614 
Image-based morphometric analysis to quantify (D) vWF stainings in PFA-fixed lung sections of 615 
WT or ALCAM-/- mice. vWF: scale bar = 200 μm and (E) Analysis of the average size if vWF+ 616 
vessels. (F) αSMA  stainings in PFA-fixed lung sections of WT or ALCAM-/- mice. ; αSMA: scale 617 
bar = 200 μm. (G) Analysis of the average size of αSMA+ vessels. (H) Analysis of the number of 618 
αSMA+ vessels in WT and ALCAM-/- mice. vWF:  n=3 mice per group, αSMA: n=4-5 mice per 619 
group. *P < 0.05, **P < 0.01, ***P < 0.001 620 
 621 
Figure 3:  Stromal ALCAM deficiency reduces lung metastasis growth in B16F10 model. 622 
Mice were injected i.v. with luciferase-expressing 1x106 B16F10 tumor cells and (A) tumor growth 623 
was monitored over time by IVIS-based analysis of in vivo luciferase activity. (B) Representative 624 
images of lungs from WT and ALCAM-/- mice at the end of the study, revealing the coverage with 625 
melanin-producing B16F10 tumor cells. (C,D) IVIS-based analysis of ex vivo luciferase activity in 626 
(C) excised lungs and (D) lung homogenates. (E) Manual counting of visible lung metastases. (F) 627 
FACS analysis of ALCAM expression of in vitro-cultured B16F10. Black histogram: anti-ALCAM 628 
staining; grey histogram: isotype control. (G) Assessment of the area covered by visible 629 
metastases (mets). (H) Distribution of small (white; diameter < 200 μm), medium (grey; diameter 630 
< 350 μm) and large (black; diameter > 350 μm) metastases in lungs of WT or ALCAM-/- mice. (A-631 
H) N=9-10 mice per group. Data from one out of three similar experiments are shown. **P < 0.01, 632 
***P < 0.001 633 
 634 
Figure 4: Stromal ALCAM deficiency reduces MC38 tumor growth and angiogenesis. Mice 635 
were i.v. injected with 3x105 MC38 tumor cells and the tumor burden was quantified after 24-26 636 
days. (A) FACS analysis of ALCAM expression by in vitro-cultured MC38 cells. Black histogram: 637 
anti-ALCAM staining; grey histogram: isotype control. (B) Representative images of tumor-638 
bearing lungs of WT and ALCAM-/- mice. (C) Quantification of the number of metastases (mets). 639 
(D) Average weight of the twelve biggest excised metastases per mouse. Pooled data from three 640 
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similar experiments involving a total of 17-18 mice per group are shown. Data are represented as 641 
mean ± SEM. (E-G) Sections of the 12 biggest metastases were stained with H&E and (E) 642 
average metastasis size was measured. (F,G) Metastases were grouped into the categories 643 
“small” (white; diameter < 2.5 mm) or “large” (black, diameter > 2.5 mm).  (F) Representative 644 
images of a small and a large metastasis. Scale bar = 1 mm. (G) Percentage-based distribution 645 
of metastasis sizes according to the genotype.  (H) Metastases sections were stained for CD31 646 
and the CD31+ area was quantified. Scale bar = 200 μm. (I) Metastases sections were stained for 647 
CD31 and NG2. The percentage of CD31+NG2+ amongst all CD31+ vessels was quantified. (E-I) 648 
N=4-5 mice per group. Data from one experiment are shown. *P < 0.05, **P < 0.01, ***P < 0.001 649 
 650 
Figure 5: Stromal ALCAM deficiency reduces LLC homing and tumor growth in the lungs. 651 
(A) FACS analysis of ALCAM expression of in vitro-cultured LLC. Black open histogram: 652 
αALCAM staining; grey tinted histogram: isotype control. (B,C): WT and ALCAM-/- mice were 653 
injected i.v. with LLC (1.5x105) cells, and the metastatic burden in the lung was analyzed on day 654 
12-14. (B) Images of tumor-bearing lungs at the end of the study. (C) Average weight of all 655 
excised metastases. (D) Total number of metastases in WT compared to ALCAM-/- mice. (B-C) 656 
N=16 mice per group. Pooled data from two independent experiments are shown.  (E,F) Mice 657 
were injected with CFSE-labeled LLC cells (1x106) i.v. followed by FACS analysis of lung single-658 
cell suspensions after 24 hours. (E) Gating scheme: Tumor cells were identified by gating on 659 
CD45- CFSE+ cells. (F) Quantification of CD45- CFSE+ LLC tumor cells. (E,F). Pooled data from 660 
three independent experiments are shown (N=24-25 mice per group). *P < 0.05, **P < 0.01, ***P 661 
< 0.001 662 
 663 
Figure 6: Stromal ALCAM deficiency leads to reduced spontaneous metastases to the 664 
lung. (A-D) Mice were s.c. injected with 2x105 luciferase-expressing LLC cells and primary 665 
tumors were resected after 21 to 24 days. (A) Primary tumor growth in WT and ALCAM-/- mice. 666 
(B) Quantification of the excised primary tumor weight. Each dot represents one mouse. (A,B) 667 
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Pooled data from two independent experiments are shown. N=28-29 mice per group. (C) Tumor 668 
vascularization was assessed by quantifying the area of CD31+ vessels. Scale bar = 200 μm, 669 
n=16-19 mice per group. Pooled data from two independent experiments are. (D) FACS analysis 670 
of ALCAM expression on single cell suspensions of ECs (CD45- CD31+) derived from lungs or 671 
from s.c. growing primary LLC tumors. Data from one out of three similar experiments shown. 672 
Black open histogram: αALCAM staining; grey tinted histogram: isotype control. (E-I) Mice with 673 
tumors ranging between 200-1000 mg on the day of resection were included in the subsequent 674 
study to monitor spontaneous metastasis. Mice were sacrificed 3 weeks after primary tumor 675 
resection and the metastatic burden was analyzed by IVIS-based measurement of luciferase 676 
activity in the respective organs, namely in lung, liver and inguinal LN.  (E) Weights of the excised 677 
tumors from mice that were included in the spontaneous metastasis study. Each dot represents 678 
one mouse. (F) Quantification of the overall rate of metastasis in ALCAM-/- and in WT mice. Black: 679 
mice with metastases detected in at least one organ. White: mice with no detectable metastases. 680 
(G) Same as in (F), but revealing the distribution of metastases in specific organs. (H-J) Rates of 681 
(H) lung, (I) LN and (J) liver metastases in WT and ALCAM-/- mice. (E-I) Pooled data from two 682 
independent experiments are shown in. N=16-18 mice per group. *P < 0.05, ***P < 0.001 683 
 684 
Supplemental Figure 1: Analysis of ALCAM expression in endothelial cells and other 685 
stromal cells  (A, B) High magnification confocal analysis of human lung tissue sections, 686 
demonstrating expression of ALCAM in CD31+ endothelial cells but not in αSMA+ mural cells. (A) 687 
CD31 - ALCAM colocalization. (B) αSMA (red)  - ALCAM (white) colocalization. Row labeling: 688 
ALCAM staining; performed with primary goat anti-ALCAM. Isotype staining: performed with 689 
primary goat isotype control antibody. For all conditions, an overview image (left), a high 690 
magnification zoomed image (middle) and a corresponding orthogonal view (right) are shown. 691 
Scale bars: 100μm (overview images) and 20μm (zoomed images). Representative images 692 
from n=2 different lung biopsy samples are shown. (C,D) Single cell suspensions were generated 693 
from murine lungs and ALCAM expression was analyzed in endothelial cells (CD45-CD31+) and 694 
 30 
other stromal cells (CD45-CD31-). (C) Depiction of the gating scheme. (D) Analysis or ALCAM 695 
expression in four different stromal cell types (differentiated based on their expression of CD31 696 
and podoplanin) was performed in WT and in ALCAM-/- mice (to confirm the specificity of the 697 
staining). Black open histogram: anti-ALCAM staining; grey tinted histogram: isotype control. 698 
Representative data from one out of two similar experiments are shown. 699 
 700 
Supplemental Figure 2: B16F10 cell homing to lungs of WT and ALCAM-/- mice. Mice were 701 
injected with CFSE-labeled B16F10 cells (1x106) i.v. 24 hours later, lungs were perfused and 702 
FACS analysis was performed on lung single-cell suspensions. (A) FACS gating scheme: Tumor 703 
cells were identified by gating on CD45- CFSE+ cells. (B) Quantification of CD45- CFSE+ LLC 704 
tumor cells. Pooled data from three independent experiments are shown. N=9 mice per group. 705 
 706 
Supplemental Figure 3: ALCAM-/- mice do not display reduced macrophage infiltration into 707 
the tumor. Mice were s.c. injected with 2x105 luciferase-expressing LLC cells and primary tumors 708 
were resected after 21 to 24 days. (A) Metastases sections were stained for F4/80 and CD206. 709 
Scale bar = 200 μm. Macrophage infiltration was analyzed by quantifying the tumor area covered 710 
by (B) F4/80+ cells and (C) F4/80+ of F4/80+CD206+ double-positive (M2-like) macrophages. 711 
Scale bar = 100 μm. N=4-5 mice per group. Data from one experiment are shown.  712 
 713 
Supplemental Figure 4: Reduced metastatic burden in ALCAM-/- mice. Mice were s.c. 714 
injected with 2x105 LLC. Primary tumors were resected after 21 to 24 days. Three weeks after 715 
primary tumor removal, metastases were identified by IVIS-based measurement of luciferase 716 
activity in the respective organs: lung (upper left), liver (upper right) and inguinal LNs (bottom). 717 
Pictures show pooled results from two independent studies. N=16-18 mice per group. 718  719 










